Advisory Services Network LLC boosted its holdings in Davita Inc (NYSE:DVA) by 1,463.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,598 shares of the company’s stock after acquiring an additional 6,176 shares during the period. Advisory Services Network LLC’s holdings in Davita were worth $495,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Commonwealth Equity Services LLC grew its holdings in Davita by 1.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 11,537 shares of the company’s stock valued at $658,000 after buying an additional 200 shares in the last quarter. Cerity Partners LLC grew its holdings in Davita by 1.4% in the 3rd quarter. Cerity Partners LLC now owns 14,284 shares of the company’s stock valued at $815,000 after buying an additional 203 shares in the last quarter. Coastline Trust Co grew its holdings in Davita by 2.2% in the 3rd quarter. Coastline Trust Co now owns 10,210 shares of the company’s stock valued at $583,000 after buying an additional 220 shares in the last quarter. SG Americas Securities LLC grew its holdings in Davita by 1.2% in the 3rd quarter. SG Americas Securities LLC now owns 35,728 shares of the company’s stock valued at $2,039,000 after buying an additional 441 shares in the last quarter. Finally, Resources Management Corp CT ADV acquired a new position in Davita in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 95.40% of the company’s stock.
Several research firms have recently issued reports on DVA. SunTrust Banks set a $90.00 target price on Davita in a report on Tuesday. Goldman Sachs Group raised Davita from a “neutral” rating to a “buy” rating in a report on Friday, January 24th. ValuEngine raised Davita from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 15th. Zacks Investment Research raised Davita from a “hold” rating to a “strong-buy” rating and set a $93.00 target price on the stock in a report on Wednesday. Finally, Wolfe Research lowered Davita from an “outperform” rating to a “market perform” rating and set a $57.00 target price on the stock. in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $71.43.
DVA opened at $86.24 on Friday. The business’s fifty day moving average is $79.12 and its 200-day moving average is $66.86. The firm has a market cap of $11.10 billion, a P/E ratio of 16.06, a price-to-earnings-growth ratio of 0.63 and a beta of 1.70. The company has a debt-to-equity ratio of 4.26, a quick ratio of 1.77 and a current ratio of 1.81. Davita Inc has a 52-week low of $43.40 and a 52-week high of $90.15.
Davita (NYSE:DVA) last released its quarterly earnings data on Monday, February 10th. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.66 by $0.20. The business had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.92 billion. Davita had a return on equity of 22.93% and a net margin of 7.12%. Davita’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.90 earnings per share. On average, research analysts predict that Davita Inc will post 5.56 earnings per share for the current fiscal year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: What are the benefits of a balanced fund?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.